1 year ago

Work programme 2017


Medium-term objective

Medium-term objective MAWP initiative Activity description Timeframe Start End Maximise benefits to public health promotion and protection by enhancing benefit-risk monitoring of authorised medicines and pharmacovigilance decisionmaking through use of high quality data, information and knowledge conduct a consultation with the pharmacovigilance stakeholders on the Explanatory note for the GVP VII on PSURs and deliver a joint NCA/Industry training on preparing and assessing PSURs Optimise administration of the EURD list by moving it to an appropriate IT platform, developing close collaboration with the network and developing risk-based criteria to determine periodicity and granularity of PSUSA scope of procedures 1.2-4 Build capacity for EU Network analysis of epidemiological data Develop inventory to facilitate access to data on real-world data Consult on mechanism for joint industry funding of studies. Initiate at least 4 EMA studies on real world evidence data Review the scientific advice process for postauthorisation studies to identify possible process improvement opportunities 1.4-4 Continue leadership of work package for 1.4-2 WebRADR on governance aspects of social media monitoring 1.2-5 Evaluate the options and feasibility to provide increased support to use of registries for targeted products on the EU market from learnings from the pilot process 1.4-1 Implement business process to receive and manage industry reported safety signals 2015 2018 2016 2020 2016 2020 2016 2020 2016 2020 Before 2018 2016 Before 2019 2016 Before After 2016 2018 Resources 2017 Financial resources (cost, thousand Euro)* 47,091 Human resources (FTEs)* 117 * Includes resources related to pharmacovigilance referrals and ICT resources involved in pharmacovigilance projects Work programme 2017 EMA/583016/2016 Page 60/123

1.6. Other specialised areas and activities Activity area This area covers EMA activities in the human medicines field, other than evaluation and monitoring of medicines. This includes work regarding the following: • Clinical trials. The growing trend for conducting clinical trials outside the EU/EEA raises the importance of ensuring the trials meet certain clinical, ethical and quality standards, and provide comprehensive, reliable data for assessment and decision-making requirements. Cooperating with international partners, the Agency contributes to improving the design, management, oversight and analysis of the clinical trials, as well as working to provide capacity-building and develop information exchanges and shared planning of GCP inspections. • Herbal medicinal products. The Agency provides scientific opinions on questions relating to herbal medicines, establishes European Union herbal monographs for traditional and wellestablished-use herbal medicines, and drafts entries to the European Union list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products. The monographs and herbal-specific scientific and regulatory guidance documents prepared by the Agency facilitate the granting of traditional use registrations and well-established-use marketing authorisations for herbal medicines, allowing them to be placed onto the EU market. • Antimicrobial resistance and availability of anti-infective treatment options. The Agency cooperates with European and international partners, including the EC, other European agencies (e.g., ECDC and EFSA), WHO, ICH, TATFAR and others, in exploring opportunities for new and effective anti-infective treatment options and other important initiatives to overcome the problem of antimicrobial resistance. Work in this field is done in regard to both human and veterinary medicines. • Public health threat preparedness. The 2009 influenza pandemic led to a review of the cross- European strategy for pandemic preparedness. In 2016 the Agency reviewed its pandemic preparedness plan and transformed it into a wider-ranging preparedness plan for emerging health threats. The Agency continuously works, in collaboration with NCAs, the EC and ECDC, to implement improvement actions to ensure high level of coordinated cross-European preparedness to act upon public health threats. Drivers Increasing globalisation of manufacturing sites and the conduct of clinical trials drives the need to ensure that the expected GXP standards are met. To do this, close collaboration with other organisations in the conduct of inspections or information exchanges will be increasingly important. This is also an opportunity for increasing efficiency gains, as collaboration provides opportunity for increased coverage without investing significant additional resources. The Clinical Trials Regulation published in May 2014 requires the Agency to develop the systems necessary for its implementation, in collaboration with the EC and the Member States. In 2017, an audit of the EU Portal and Database will take place and, on the basis of the audit report, the EMA Management Board will confirm if the EU Portal and Database have achieved full functionality. According to the adopted delivery timeframe, the Regulation will then become applicable by October 2018. Work programme 2017 EMA/583016/2016 Page 61/123

2017 Work Programme
Work Programme 2011 - ERA - Europa
VMGN 11 - Veterinary Medicines Directorate - Defra
IFAH-Europe annual report 2006 - Bundesverband für Tiergesundheit
How TOPRA in Spain will work - presentation
final programme - digital edition - seg/esg congress 2013
Dr. Monica Vinhas de Souza - EHC
ANNUAL REPORT - Bundesverband für Tiergesundheit
MHRA powerpoint template - TOPRA
EFAMA Conference Programme
(CPD) Programme for Pharmaceutical Staff
FP7 ICT Work Programme 2013 - RTD
VMGN 01 - Controls of Veterinary Medicines